Guardant Health (NASDAQ:GH) CTO Darya Chudova Sells 7,738 Shares

Guardant Health, Inc. (NASDAQ:GH) CTO Darya Chudova sold 7,738 shares of Guardant Health stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the transaction, the chief technology officer directly owned 70,635 shares of the company’s stock, valued at approximately $12,573,030. This represents a 9.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Guardant Health Stock Performance

Guardant Health stock opened at $183.10 on Friday. The firm has a market capitalization of $24.57 billion, a price-to-earnings ratio of -52.46 and a beta of 1.57. Guardant Health, Inc. has a fifty-two week low of $55.38 and a fifty-two week high of $183.51. The stock’s fifty day moving average is $160.71 and its two-hundred day moving average is $127.10.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. During the same quarter in the prior year, the business earned ($0.44) EPS. The company’s quarterly revenue was up 44.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Guardant Health News Summary

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook brightened, supporting investor confidence in continued revenue growth. Guardant Health Nears Buy Point As Sales Outlook Brightens
• Positive Sentiment: A comparison of second-quarter testing and diagnostics companies highlighted Guardant Health’s strong performance. The company’s revenue rose 44.3% year over year to approximately $335 million and exceeded analyst expectations, while its quarterly loss was narrower than forecast. Testing & diagnostics services stocks Q2 results: Benchmarking Guardant Health
• Positive Sentiment: The stock reached a new one-year high, reflecting strong momentum and investor demand following its recent rally. The move could attract additional momentum-oriented buyers, though it also raises the risk of profit-taking. Guardant Health Reaches New 1-Year High – What’s Next?
• Neutral Sentiment: Director Musa Tariq sold 116 shares for about $20,300, reducing his position by 1%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, making it a limited and less concerning signal. SEC Form 4 filing
• Negative Sentiment: Several insiders reported sales: Director Alex M. Azar II sold 826 shares for approximately $144,550, Director Steve Krognes sold 6,674 shares for roughly $1.17 million, and CTO Darya Chudova sold 7,738 shares for about $1.38 million. The transactions reduced their holdings substantially and could raise profit-taking concerns, although the sales were disclosed through SEC filings and some were conducted under pre-arranged plans. Insider sale SEC filing

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GH. Allworth Financial LP boosted its holdings in shares of Guardant Health by 12.4% in the 2nd quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after buying an additional 118 shares during the period. GAMMA Investing LLC raised its stake in Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after acquiring an additional 122 shares during the period. First Pacific Financial lifted its holdings in Guardant Health by 33.1% in the first quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares during the last quarter. ABS Investment Management LLC bought a new position in Guardant Health in the second quarter worth about $345,069,000. Finally, MCF Advisors LLC boosted its stake in Guardant Health by 755.0% in the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after acquiring an additional 151 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GH. Royal Bank Of Canada upped their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Bank of America lifted their price objective on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Mizuho upped their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Sanford C. Bernstein reiterated an “outperform” rating and set a $210.00 target price on shares of Guardant Health in a report on Thursday, September 10th. Finally, UBS Group increased their target price on Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $188.12.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.